




YPSOMED
SELF CARE SOLUTIONS

The Device Perspective of Quality in Manufacturing

June 7, 2005


Agenda

- Scope of Presentation
- Background, Introduction
- Impact of Poor Quality
- Main Influences on Quality
- Tools and Methodology
- Summary
- Discussion / Questions



Context of Presentation


- Medical devices for drug delivery: stand alone or combinatorial products
- Quality from perspective of management / business




- Medical device design and manufacturer
 - Focus on self-injection devices for therapeutic large molecules e.g. peptides, MCAs
 - 19 years old
 - \$200 million annual turnover; 850 employees
 - Publically traded on SWX; market cap. \$1.1 billion
-
- > 3 million devices with lifetime > 2 years (20-40 parts)
 - > 50 million disposable devices with lifetime 5 – 15 days (7 – 10 parts)
 - >150 million sterile single use devices (5 parts)

Background: Ypsomed – Product Examples


Combined



Disposable prefilled pen



Disposable auto-injector



510k



Example: injectable biotech drug
prefilled syringe or cartridge
safety or self-injection device

- Annual cost of drug in treatment: \$20'000
- Other associated treatment costs: \$10'000
- Annual cost of devices: \$ 250

- Cost of handling one device complaint: \$1000's

Impact of Poor Quality

company	POTENTIAL IMPACT ON			
	direct costs	liability	reputation	sales
Pharma / Biotech	+++++ (1)	++	---	----
Device	+++ (2)	++++	--	--

(1) complaint handling, lost drug, lost market, administration

(2) guarantees, complaint handling, corrective action

Massive Increase in Quality Demands

- ⦿ Convergence of expectations for medical devices and drug product
- ⦿ Traceability requirements increased back through several layers of suppliers
 - higher performing QA systems required
- ⦿ Post market surveillance and corrective action expectations increased
- ⦿ Cost and risk of complaints has increased
 - increased liability risk
- ⦿ Vigilance of pharma and biotech industry has increased
 - realisation of vulnerability to quality issues in devices

Two aspects of quality

quality in	measured by	timeframe of impact
Design	<ul style="list-style-type: none">- patient complaints on handling / ease of use- internal wastage- product failure on market	<ul style="list-style-type: none">- immediately patient has product- during production- late in lifecycle of product
Manufacturing	<ul style="list-style-type: none">- internal wastage- product failure on market	<ul style="list-style-type: none">- during production- late in lifecycle of product

Perhaps the single most important factor in quality in manufacturing is the quality of the design

Determined by:

- Simplicity → remove unnecessary complexity
- Robustness → account for variability on manufacturing
- Manufacturability
- Well specified product and process


Manufacturing aspects are an integral part of medical device design

Specification of Product and Components

In my experience, most quality problems in manufacturing arise from insufficiently or poorly specified products, components or raw materials rather than a poorly executed manufacturing process

- focus on specifications
(a verification / validation to incomplete specifications is useless)
- understand supplier processes well enough to specify product
- audit suppliers frequently


Design Development & Maintenance Process



- ⑥ CAD / Kinematic animations
- ⑥ Finite Element Analysis
- ⑥ Mold Flow
- ⑥ Tolerance Analysis
- ⑥ Risk Analysis
- ⑥ Design FMEA
- ⑥ Process FMEA

- ⑥ Mishandling analysis and studies


Auto-Injector Easy cutout



Specifications of components and product; validation and IPC parameters


Risk of damaging product during manufacturing → assembly processes, transport, automation
Process verification and validation parameters

Design – PFMEA Procedures



Management and technical reviews


Key quality decision points
- delay if insufficiently specified or
not robust



- ◉ API / chemical quality control:
 - characterisation of raw materials possible
 - focus on ensuring homogeneity of solution, powder etc. → assay analysis etc.
 - by definition then 100% of batch is released
- ◉ Medical device quality control
 - complete characterisation of components hardly possible – but key is sufficient specification
 - focus on consistency of process parameters, key dimensions, elasticity parameters etc.
 - in addition need to identify individual deviations
 - thousands or millions of individual devices, tests often destructive
 - by definition release of batches through statistical confidence levels

- ◉ Statistical in-process control (IPC)
Example: injection moulding
 - tools will degredate
 - focus on identifying that moment
 - regular sampling
 - cavity separation to ensure isolation of problem
 - numerous environmental parameters will influence dimensional and rheological characteristics of plastics
 - environmental monitoring
 - statistical IPC of dimensional parameters
 - intervention levels


- Example of IPC



- ④ Design testing into product

→ every product must function, but virtually impossible to test each individual product unless designed into product


→ these must be integral part of the design



Example: Disposable Pen assembly

- torque tests carried out as pen initial dose set
- dosing and resistance tests carried out as pen assembled (extra doses designed into pen !!)
- printing verified to 100% with cameras

video sequence OptiSet



Example: Electronic Products

Possibility of self testing

- self-testing as device starts up
- monitoring of forbidden configuration changes
- diagnostic features to allow failure analysis
if product malfunctions and returns from market
- secondary circuits which monitor functioning


simulation electronics

- ① 100% Testing may be appropriate

In electronics, challenge is low component yields, poor quality systems in supplier industry, sensitivity of manufacturing processes and complexity of devices

- chips have low yields and show frequent deviations
 - 100% testing of chips
- components supplied on rolls from industry without medical device industry standards, incorrect labelling possible
 - 100% testing of individual rolls
 - 100% testing of each complete circuit board
- functionality of final product could be damaged in manufacturing process (ESD)
 - 100% test of final product

- ◉ Market feedback will usually indicate manufacturing or design risks: it is important to react before a major quality issue occurs
 - trending is insufficient, action on findings required
 - product improvement teams
 - complaint reduction targets
 - waste reduction targets
 - waste as an indication of defect potential
 - react to single complaints or deviations, don't wait for an accumulation as it is probably too late then
 - maintain design team into post-market surveillance period



Summary

- Prevention
 - well specified products and raw materials
 - good control over suppliers (understand their processes)
 - good, robust design
 - well thought out, robust process
 - zero tolerance of weaknesses, delay launch if required
- Monitoring
 - In-process control strategies
 - Consider and design in 100% testing
- Correction
 - Market vigilance and corrective action